Literature DB >> 19411015

Non-myeloablative allogeneic hematopoietic stem cell transplantation.

Nonniekaye Shelburne1, Margaret Bevans.   

Abstract

OBJECTIVE: To review the literature related to nonmyeloablative stem cell transplantation (SCT), and the unique characteristics and patient population to which it applies. DATA SOURCES: Research studies, research and clinical reviews, clinical experience.
CONCLUSION: Nonmyeloablative SCT has demonstrated effective and safe application in a heterogeneous population not otherwise eligible for an allogeneic transplantation. Although many principles are based on those of conventional myeloablative transplantation, the engraftment kinetics, patient selection, and regimen-related complications are distinct. IMPLICATIONS FOR NURSING PRACTICE: Nurses must be knowledgeable about nonmyeloablative SCT, including the provision of individualized care for a heterogeneous population. This can include non-traditional transplant indications, elderly cancer patients, and those with comorbidities.

Entities:  

Mesh:

Year:  2009        PMID: 19411015      PMCID: PMC2728008          DOI: 10.1016/j.soncn.2009.03.006

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  62 in total

1.  Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Authors:  J Mehta; L I Gordon; M S Tallman; J N Winter; A M Evens; A O Evens; O Frankfurt; S F Williams; D Grinblatt; L Kaminer; R Meagher; S Singhal
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

2.  Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

Authors:  M F Bevans; S Marden; N K Leidy; K Soeken; G Cusack; P Rivera; H Mayberry; M R Bishop; R Childs; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

Review 3.  Hemopoietic chimerism following stem cell transplantation.

Authors:  Shaun R McCann; Mireille Crampe; Karen Molloy; Mark Lawler
Journal:  Transfus Apher Sci       Date:  2005-02       Impact factor: 1.764

4.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Daniel A Pollyea; Masha Kocherginsky; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Todd Zimmerman; Sonali Smith; Lucy Godley; Michael Thirman; Christopher Daugherty; Martine Extermann; Richard Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

5.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

Review 6.  Comorbidity indices in hematopoietic stem cell transplantation: a new report card.

Authors:  J Alamo; M Shahjahan; H M Lazarus; M de Lima; S A Giralt
Journal:  Bone Marrow Transplant       Date:  2005-09       Impact factor: 5.483

7.  Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.

Authors:  C Cordonnier; S Maury; H Esperou; C Pautas; J Beaune; M Rodet; J-L Lagrange; H Rouard; J-L Beaumont; F Bassompierre; E Glückman; M Kuentz; I Durand-Zaleski
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

Review 8.  Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy.

Authors:  R Champlin; I Khouri; S Kornblau; J Molldrem; S Giralt
Journal:  Curr Opin Oncol       Date:  1999-03       Impact factor: 3.645

9.  Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

Authors:  Raymond Wong; Munir Shahjahan; Xuemei Wang; Peter F Thall; Marcos De Lima; Issa Khouri; James Gajewski; Jorge Alamo; Daniel Couriel; Borje S Andersson; Michelle Donato; Chitra Hosing; Krishna Komanduri; Paolo Anderlini; Jeffrey Molldrem; Naoto T Ueno; Elihu Estey; Cindy Ippoliti; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-02       Impact factor: 5.742

Review 10.  Stem cell transplantation: past, present and future.

Authors:  E D Thomas
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1997       Impact factor: 4.291

View more
  3 in total

1.  Long-Lasting Impact of Neonatal Exposure to Total Body Gamma Radiation on Secondary Lymphoid Organ Structure and Function.

Authors:  Javier Rangel-Moreno; Maria de la Luz Garcia-Hernandez; Rosalio Ramos-Payan; Jamie Biear; Eric Hernady; Mark Y Sangster; Troy D Randall; Carl J Johnston; Jacob N Finkelstein; Jacqueline P Williams
Journal:  Radiat Res       Date:  2015-09-23       Impact factor: 2.841

2.  Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantation.

Authors:  Jacob Andrade; Shundi Ge; Goar Symbatyan; Michael S Rosol; Arthur J Olch; Gay M Crooks
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-19       Impact factor: 5.742

3.  Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.

Authors:  Yue Yang; Nikolas L Jorstad; Christine Shiao; Makenzie K Cherne; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2013-04-06       Impact factor: 3.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.